{
    "clinical_study": {
        "@rank": "70644", 
        "acronym": "START", 
        "arm_group": [
            {
                "arm_group_label": "Human Mesenchymal Stem Cells", 
                "arm_group_type": "Experimental", 
                "description": "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes."
            }, 
            {
                "arm_group_label": "Plasma-Lyte A", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study to\n      assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human\n      Mesenchymal Stem Cells infusion in patients with Acute Respiratory Distress Syndrome (ARDS).\n       This study is the extension of the Phase 1 pilot study (NCT01775774).  Patients will be\n      randomized to receive Human Mesenchymal Stem Cells infusion or placebo in a 2:1 allocation.\n      Patients will be followed daily for adverse events through day 28, death or hospital\n      discharge, whichever occurs first. Vital status will be collected at 6 and 12 months after\n      study enrollment."
        }, 
        "brief_title": "Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome (START)", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Respiratory Distress Syndrome, Adult", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult", 
                "Acute Lung Injury"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients will be eligible for inclusion if they meet all of the below criteria. Criteria\n        1-3 must all be present within a 24-hour time period and at the time of enrollment:\n\n        Acute onset (defined below) of:\n\n          1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a\n             PaO2/FiO2 ratio < 200 with at least 8 cm H2O positive end-expiratory airway pressure\n             (PEEP)\n\n          2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph\n\n          3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.\n\n        Exclusion Criteria:\n\n          1. Age less than 18 years\n\n          2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of\n             ARDS\n\n          3. Pregnant or breast-feeding\n\n          4. Prisoner\n\n          5. Presence of any active malignancy (other than non-melanoma skin cancer) that required\n             treatment within the last 2 years\n\n          6. Any other irreversible disease or condition for which 6-month mortality is estimated\n             to be greater than 50%\n\n          7. Moderate to severe liver failure (Childs-Pugh Score > 12)\n\n          8. Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen\n\n          9. Patient, surrogate, or physician not committed to full support (exception: a patient\n             will not be excluded if he/she would receive all supportive care except for attempts\n             at resuscitation from cardiac arrest)\n\n         10. Major trauma in the prior 5 days\n\n         11. Lung transplant patient\n\n         12. No consent/inability to obtain consent\n\n         13. Moribund patient not expected to survive 24 hours\n\n         14. WHO Class III or IV pulmonary hypertension\n\n         15. Documented deep venous thrombosis or pulmonary embolism within past 3 months\n\n         16. No arterial line/no intent to place an arterial line\n\n         17. No intent/unwillingness to follow lung protective ventilation strategy or fluid\n             management protocol\n\n         18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory\n             ventilation (HFOV)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097641", 
            "org_study_id": "UCSF-hMSC-ARDS-P2", 
            "secondary_id": "1U01HL108713-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Human Mesenchymal Stem Cells", 
                "description": "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.", 
                "intervention_name": "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Plasma-Lyte A", 
                "description": "Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.", 
                "intervention_name": "Plasma-Lyte A", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells", 
            "Acute Respiratory Distress Syndrome"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "contact": {
                    "email": "michael.matthay@ucsf.edu", 
                    "last_name": "Michael A Matthay, MD", 
                    "phone": "415-353-1206"
                }, 
                "contact_backup": {
                    "email": "hanjing.zhuo@ucsf.edu", 
                    "last_name": "Hanjing Zhuo, MPH", 
                    "phone": "415-502-7434"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California San Francisco"
                }, 
                "investigator": [
                    {
                        "last_name": "Michael A Matthay, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Kathleen D Liu, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jenny Wilson, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rvojnik@stanford.edu", 
                    "last_name": "Rosemary Vojnik", 
                    "phone": "650-723-7409"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University"
                }, 
                "investigator": [
                    {
                        "last_name": "Joseph E Levitt, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Angela Rogers, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kcosgrove@partners.org", 
                    "last_name": "Katherine Cosgrove, RN", 
                    "phone": "617-726-3498"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Taylor B Thompson, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jeanine Wiener-Kronish, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ed Bajwa, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55108"
                    }, 
                    "name": "University of Minnesota Medical Center"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "parnishja@upmc.edu", 
                    "last_name": "Julie Parnish", 
                    "phone": "412-624-7441"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "University of Pittsburgh"
                }, 
                "investigator": [
                    {
                        "last_name": "Michael Donahoe, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Luis Ortiz, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome", 
        "overall_contact": {
            "email": "michael.matthay@ucsf.edu", 
            "last_name": "Michael A Matthay, MD", 
            "phone": "415-353-1206"
        }, 
        "overall_contact_backup": {
            "email": "hanjing.zhuo@ucsf.edu", 
            "last_name": "Hanjing Zhuo, MPH", 
            "phone": "415-502-7434"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Michael A Matthay, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of pre-specified infusion associated events occurring within 6 hours of study infusion", 
                "safety_issue": "Yes", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Any cardiac arrest or death within 24 hours of study infusion", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Any unexpected severe adverse events in two groups", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097641"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Michael A. Matthay", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Respiratory efficacy endpoints which include lung injury score, PaO2/FiO2 ratio and oxygenation index at day 3.", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Systemic efficacy endpoints which include SOFA score, ventilator-free days, organ failure free days,  mortality, et al.", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Biological efficacy endpoints which includes serial levels of plasma and urine biomarkers.", 
                "safety_issue": "No", 
                "time_frame": "3 days"
            }
        ], 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Massachusetts General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Stanford University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Pittsburgh", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Michael A. Matthay", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}